Organon

OGN · NYSE

$13.76+$0.01 (+0.07%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $13.75

Latest news

Press releaseOct 19, 7:30 AM ETBusiness Wire
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Press releaseOct 16, 7:30 AM ETBusiness Wire
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Press releaseOct 1, 8:00 AM ETBusiness Wire
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Press releaseSep 14, 7:30 AM ETBusiness Wire
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
Press releaseAug 27, 9:00 AM ETGlobe Newswire
National Can-RISE Study to Help Close Critical Gaps in Menopause Research
Press releaseAug 11, 7:30 AM ETBusiness Wire
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
Press releaseJul 31, 8:30 AM ETBusiness Wire
Organon Announces Quarterly Dividend
Press releaseJul 24, 8:00 AM ETBusiness Wire
New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
Press releaseJul 16, 7:30 AM ETBusiness Wire
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Press releaseJul 7, 8:00 AM ETBusiness Wire
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting
Press releaseJun 25, 1:58 PM ETPRNewswire
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders?
Press releaseJun 24, 2:28 PM ETBusiness Wire
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
Press releaseJun 23, 5:30 AM ETBusiness Wire
Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA
Press releaseJun 22, 7:30 AM ETBusiness Wire
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
NewsJun 18, 6:08 AM ET
Organon And Samsung Bioepis Expand Their Development And Commercialization Agreement To Provide OGN With Commercialization Rights In Canada To PYZCHIVA, Samsung Bioepis's Biosimilar Referencing STELARA
Press releaseJun 18, 6:00 AM ETBusiness Wire
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
Press releaseJun 10, 7:30 AM ETBusiness Wire
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
Press releaseMay 15, 7:30 AM ETBusiness Wire
Organon to Present New Research on Access and Value at ISPOR 2026
Press releaseMay 14, 5:25 PM ETPRNewswire
Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?
Press releaseMay 4, 2:55 PM ETPRNewswire
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?
NewsMay 1, 2:35 PM ETCaroline Ryan
Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy
NewsApr 30, 8:08 AM ET
Organon Q1 Adj. EPS $0.71 Misses $0.83 Estimate, Sales $1.460B Miss $1.484B Estimate
Press releaseApr 30, 7:30 AM ETBusiness Wire
Organon Reports Results for the First Quarter Ended March 31, 2026
NewsApr 30, 6:53 AM ETSnigdha Gairola
Organon Stock's Momentum Score Jumps As $11.75 Billion Sun Pharma Takeover Deal Sparks Global Pharma Consolidation Push
Press releaseApr 29, 10:00 AM ETPRNewswire
European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
Press releaseApr 29, 7:30 AM ETBusiness Wire
Organon Cancels First Quarter Earnings Call
Press releaseApr 29, 5:30 AM ETBusiness Wire
European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
Press releaseApr 28, 12:36 PM ETBusiness Wire
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
NewsApr 27, 1:16 PM ETPiero Cingari
Nasdaq 100 Eases From Records As Brent Tops $108: Stock Market Today
Press releaseApr 27, 11:24 AM ETPRNewswire
Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders?
Press releaseApr 27, 11:02 AM ETGlobe Newswire
Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical
NewsApr 27, 8:33 AM ETRishabh Mishra
Stock Market Today: Dow Futures Fall, S&P 500 Gains As Trump Halts Iran Talks— Organon, SAP, Cheetah Net Supply Chain Service In Focus (UPDATED)
NewsApr 27, 5:57 AM ETAkanksha Bakshi
Why Is Organon Stock Skyrocketing Monday?
NewsNov 11, 11:40 AM ETAvi Kapoor
Organon Analysts Cut Their Forecasts Following Q3 Results
Press releaseSep 9, 11:27 AM ETPRNewswire
Kuehn Law Encourages Investors of Organon & Co. to Contact Law Firm
Press releaseAug 13, 10:15 AM ETPRNewswire
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation
Press releaseJul 22, 3:34 PM ETGlobe Newswire
Contact Levi & Korsinsky by July 22, 2025 Deadline to Join Class Action Against Organon & Co.(OGN)
Press releaseJul 22, 9:47 AM ETBusiness Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
Press releaseJul 22, 8:45 AM ETPRNewswire
Organon & Co. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN
Press releaseJul 22, 8:00 AM ETGlobe Newswire
ORGANON FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit
Press releaseJul 21, 4:32 PM ETGlobe Newswire
The Gross Law Firm Notifies Organon & Co. Investors of a Class Action Lawsuit and Upcoming Deadline – OGN
Press releaseJul 21, 4:02 PM ETPRNewswire
OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN
Press releaseJul 21, 3:51 PM ETPRNewswire
OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

National Can-RISE Study to Help Close Critical Gaps in Menopause Research

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

Organon Announces Quarterly Dividend

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting

Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders?

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

Organon And Samsung Bioepis Expand Their Development And Commercialization Agreement To Provide OGN With Commercialization Rights In Canada To PYZCHIVA, Samsung Bioepis's Biosimilar Referencing STELARA

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Organon to Present New Research on Access and Value at ISPOR 2026

Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?

Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?

Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy

Organon Q1 Adj. EPS $0.71 Misses $0.83 Estimate, Sales $1.460B Miss $1.484B Estimate

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Stock's Momentum Score Jumps As $11.75 Billion Sun Pharma Takeover Deal Sparks Global Pharma Consolidation Push

European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

Organon Cancels First Quarter Earnings Call

European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

Nasdaq 100 Eases From Records As Brent Tops $108: Stock Market Today

Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders?

Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical

Stock Market Today: Dow Futures Fall, S&P 500 Gains As Trump Halts Iran Talks— Organon, SAP, Cheetah Net Supply Chain Service In Focus (UPDATED)

Why Is Organon Stock Skyrocketing Monday?

Organon Analysts Cut Their Forecasts Following Q3 Results

Kuehn Law Encourages Investors of Organon & Co. to Contact Law Firm

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation

Contact Levi & Korsinsky by July 22, 2025 Deadline to Join Class Action Against Organon & Co.(OGN)

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Organon & Co. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN

ORGANON FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit

The Gross Law Firm Notifies Organon & Co. Investors of a Class Action Lawsuit and Upcoming Deadline – OGN

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm